RELMADA THERAPEUTICS, INC. Operating Lease, Expense
RELMADA THERAPEUTICS, INC. (RLMD) reported Operating Lease, Expense of $47.50 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $47.50K, a 11.55% decline year-over-year.
- RELMADA THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $45.70K, a 2.01% increase year-over-year.
- RELMADA THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-12-31 was $49.10K, a 14.16% decline year-over-year.
- RELMADA THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $43.10K, a 25.17% decline year-over-year.
- RELMADA THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $190.70K, a 19.50% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $236.90K, a 16.47% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $283.60K.
| Period end | Operating Lease, Expense 1 month | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $47.50K 10-Q · filed 2026-08-06 | $93.20K 10-Q · filed 2026-08-06 | $142.30K derived: sum of 3 quarters · filed 2026-08-06 | $185.40K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $45.70K 10-Q · filed 2026-05-12 | $94.80K derived: sum of 2 quarters · filed 2026-05-12 | $137.90K derived: sum of 3 quarters · filed 2026-05-12 | $191.60K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $49.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $92.20K derived: sum of 2 quarters · filed 2026-03-19 | $145.90K derived: sum of 3 quarters · filed 2026-08-06 | $190.70K 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $43.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $96.80K derived: sum of 2 quarters · filed 2026-08-06 | $141.60K 10-Q · filed 2025-11-13 | $198.80K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $53.70K 10-Q · filed 2026-08-06 | $98.50K 10-Q · filed 2026-08-06 | $155.70K derived: sum of 3 quarters · filed 2026-08-06 | $213.30K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $44.80K 10-Q · filed 2026-05-12 | $102.00K derived: sum of 2 quarters · filed 2026-05-12 | $159.60K derived: sum of 3 quarters · filed 2026-05-12 | $219.30K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $57.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $114.80K derived: sum of 2 quarters · filed 2026-03-19 | $174.50K derived: sum of 3 quarters · filed 2026-03-19 | $236.90K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $57.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $117.30K derived: sum of 2 quarters · filed 2025-11-13 | $179.70K 10-Q · filed 2025-11-13 | $249.80K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $59.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $122.10K 10-Q · filed 2025-08-07 | $192.20K derived: sum of 3 quarters · filed 2025-08-07 | $268.70K derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $62.40K 10-Q · filed 2025-05-12 | $132.50K derived: sum of 2 quarters · filed 2025-05-12 | $209.00K derived: sum of 3 quarters · filed 2025-05-12 | $294.30K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $12.00K 10-K · filed 2024-03-19 | $70.10K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $146.60K derived: sum of 2 quarters · filed 2025-03-27 | $231.90K derived: sum of 3 quarters · filed 2025-03-27 | $283.60K 10-K · filed 2025-03-27 | $14.50K 10-K · filed 2024-03-19 |
| 2023-09-30 | $76.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $161.80K derived: sum of 2 quarters · filed 2024-11-07 | $213.50K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $85.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $137.00K 10-Q · filed 2024-08-07 | ||||
| 2023-03-31 | $51.70K 10-Q · filed 2024-05-08 | |||||
| 2022-06-30 | $24.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $44.00K 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | $19.50K 10-Q · filed 2023-05-11 | |||||
| 2020-09-30 | $41.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $82.80K derived: sum of 2 quarters · filed 2020-11-12 | $124.40K 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $41.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $83.00K 10-Q · filed 2020-08-12 | ||||
| 2020-03-31 | $41.60K 10-Q · filed 2020-05-15 | |||||
| 2019-09-30 | $23.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $47.10K derived: sum of 2 quarters · filed 2020-11-12 | $70.30K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $23.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $46.80K 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | $23.20K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |